NetraMark Holdings' NetraAI platform won the 2026 BioTech Breakthrough Award for Analytics Platform of the Year, recognized for its use of explainable AI to uncover hidden patient response patterns in clinical trials. This technology helps drug developers better understand patient subgroups and improve clinical trial design, addressing the high failure rate and cost in drug development. The award highlights NetraAI's role in enhancing decision-making in pharmaceutical research, with ongoing peer-reviewed validation and expanding partnerships. This recognition supports NetraMark's mission to optimize drug development using advanced AI analytics.
NetraMark's NetraAI platform received the 2026 BioTech Breakthrough Award for Analytics Platform of the Year. For readers following the health sector, here is Pluang's market snapshot as of Nov 05, 2026 19:01 WIB: 94 of 150 priced US health stocks rose today. Mesoblast Limited (MESO) traded at USD 14.79 with a 3.50% increase, Edwards Lifesciences Corporation (EW) was priced at USD 102.74, up 3.39%, and LifeStance Health Group Inc. (LFST) rose 3.24% to USD 14.67.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
